Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 18;43(2):150-165.
doi: 10.24272/j.issn.2095-8137.2021.363.

Engineered T cells and their therapeutic applications in autoimmune diseases

Lei Bao  1 , Xiao-Chen Bo  1 , Huai-Wen Cao  1 , Chen Qian  1 , Zeng Wang  2 , Bin Li  3
Affiliations
Review

Engineered T cells and their therapeutic applications in autoimmune diseases

Lei Bao et al. Zool Res. .

Abstract
in English, Chinese

Chimeric antigen receptor T cells (CAR-T cells) are engineered recombinant T cells, which were initially used to treat hematopoietic malignancies and are now widely used in the treatment of various diseases. Considering their intrinsic targeting efficiency, CAR-T cells show considerable potential in the treatment of autoimmune diseases. Furthermore, regulatory T cells (Treg), a subset of CD4 T cells exhibiting immunosuppressive functions, have attracted increasing attention regarding CAR-Treg cell production. In this review, we report on recent developments in preclinical and clinical studies on CAR-T cells in autoimmune diseases and provide an outlook on opportunities and challenges of CAR-T application in such diseases.

嵌合抗原受体T细胞（CAR-T细胞）是经过设计的重组T细胞，最初被用于治疗造血性恶性肿瘤，现在被广泛用于治疗各种疾病。因为其高效的靶向性，CAR-T细胞在治疗自身免疫性疾病方面显示出相当大的潜力。此外，调节性T细胞（Treg）是CD4 +T细胞的一个亚群，表现出免疫抑制功能，CAR-Treg细胞在自身免疫性疾病中的应用也引起了越来越多的关注。该综述介绍了CAR-T细胞在自身免疫性疾病中的临床前和临床研究的最新进展，并对CAR-T在此类疾病中应用的机会和挑战进行了展望。.

Keywords: Autoimmune diseases; Cell immunotherapy; Chimeric antigen receptor T cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanism of autoimmune diseases
Figure 2
Figure 2
Four generations of CARs
Figure 3
Figure 3
Application of CAR-T cells in animal model of SLE
Figure 4
Figure 4
Application of CAR-T cells in animal model of type 1 diabetes
Figure 5
Figure 5
Application of CAR-Treg cells in animal model of colitis
Figure 6
Figure 6
Application of CAR-Treg cells in animal model of MS
Figure 7
Figure 7
Application of CAR-T cells in animal model of RA
Figure 8
Figure 8
Application of CAAR-T cells in animal model of PV
See this image and copyright information in PMC

References

    1. Abramson JS Anti-CD19 CAR T-cell therapy for B-cell non-hodgkin lymphoma. Transfusion Medicine Reviews. 2020;34(1):29–33. doi: 10.1016/j.tmrv.2019.08.003. - DOI - PubMed
    1. Acharya UH, Dhawale T, Yun S, Jacobson CA, Chavez JC, Ramos JD, et al Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Review of Hematology. 2019;12(3):195–205. doi: 10.1080/17474086.2019.1585238. - DOI - PubMed
    1. Adams SM, Bornemann PH Ulcerative colitis. American Family Physician. 2013;87(10):699–705. - PubMed
    1. Amagai M, Klaus-Kovtun V, Stanley JR Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991;67(5):869–877. doi: 10.1016/0092-8674(91)90360-B. - DOI - PubMed
    1. Amagai M, Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawa T Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. The Journal of Clinical Investigation. 2000;105(5):625–631. doi: 10.1172/JCI8748. - DOI - PMC - PubMed

Substances